VahatiCor, Inc. — SEC Form D Filing
VahatiCor, Inc. filed an SEC Form D on October 20, 2026, reporting $30.38M raised in Medical Devices.
Form D filing details
- Filing
- SEC Form D
- Filing date
- October 20, 2026
- Amount reported
- $30.38M
- Round stage
- Series A
- Industry
- Medical Devices
- Website
- https://vahaticor.com/
What the company does
Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
Patients with coronary microvascular dysfunction (CMD) suffer from persistent chest pain and shortness of breath that cannot be detected by standard angiograms. For many individuals, these symptoms continue despite medication, leaving them with limited interventional treatment options.
Solution
VahatiCor is developing the A-FLUX Reducer System, an hourglass-shaped nitinol mesh device delivered via catheter into the coronary sinus. The implant creates a controlled narrowing to modulate blood flow and improve coronary microvascular perfusion.
Why now
Emerging clinical consensus is highlighting ischemia with non-obstructive coronary arteries (INOCA/CMD), driving urgent clinical demand for transcatheter interventions targeting coronary microvasculature.
Verdict
This cleared because investors pattern-matched the asset directly to Neovasc's clinical precedent in the coronary sinus, not because coronary microvascular dysfunction had established a frictionless reimbursement path. The syndicate bet that interventional cardiologists, frustrated by non-obstructive coronary disease (INOCA) patients cycling through catheterization labs without an actionable fix, will eagerly adopt a mechanical implant that offers procedural closure. Upside remains bounded by the grueling health economics of microvascular therapies: without an unquestionable sham-controlled efficacy signal and dedicated new technology add-on payments, hospital value-analysis committees will treat it as a cost center rather than a growth engine.
Source: SEC EDGAR Form D filing